Latest Breaking News On - Shefali agarwal - Page 4 : comparemela.com

Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities

Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalDanielle guyot caparrosJulien miaraJudith grecietEmmanuel huynhArthur rouillShefali agarwalOnxeo sa euronextGustave roussyInstitut curieAmerican association for cancer researchCongress onCancer consortiumDrug administrationCompany group

Onxeo S A : Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities

> Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally > Cash position of €26.9 million as of June 30, 2022 > Financial visibility assured until Q2 2023 Regulatory

United statesFrance generalDanielle guyot caparrosJulien miaraJudith grecietEmmanuel huynhArthur rouillShefali agarwalOnxeo sa euronextGustave roussyInstitut curieAmerican association for cancer researchCongress onCancer consortiumDrug administrationCompany group

High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Ph

PARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR)n in particular against rare or resistant forms of cancer, today announced that.

France generalCatherine goupillonMarie curieMarie dutreixEmmanuel huynhArthur rouillShefali agarwalKriibskrank kannerLe tourneauOnxeo sa euronextInstitut curieCompany groupRegulatory newsEuronext growthNasdaq firstHigh grade glioma

Onxeo S A : High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie

Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage

France generalCatherine goupillonMarie curieMarie dutreixEmmanuel huynhArthur rouillShefali agarwalKriibskrank kannerLe tourneauOnxeo sa euronextInstitut curieCompany groupRegulatory newsEuronext growthNasdaq firstHigh grade glioma

Onxeo: Initial IND Application for AsiDNA Granted Study May Proceed by the U S FDA

Onxeo: Initial IND Application for AsiDNA Granted Study May Proceed by the U S FDA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalShefali agarwalArthur rouillOnxeo sa euronextEmmanuel huynhDrug administrationCompany groupEuronext growth parisNasdaq first north copenhagenEuronext parisStrategic communicationNasdaq first north